According to the market research, the sales value of Anlotinib in the Chinese market increases year by year from 2018 to 2020. Especially in 2019, sales reached CNY 650 million, an increase of about 20 times year on year. The main reason is that Anlotinib has been welcomed by hospitals and patients based on its therapeutic advantages since its approval in 2018. The CAGR of the sales value of Anlotinib in the Chinese market is 444.49% from 2018 to 2020.
The analyst predicts that the sales of Rotinib in the Chinese market will continue to grow from 2021 to 2025, with the increase in the number of cancer patients. Lung cancer is the leading cause of human cancer deaths, accounting for about one-fifth of all cancer deaths. According to the data on the number of new cancers in 2020 released by WHO, the number of new lung cancers and deaths in China in 2020 is 280,000 and 710,000, respectively, which are the highest in the world. Anlotinib-treated non-small cell lung cancer (NSCLC) accounts for 80% to 90% of lung cancer in China. The huge patient population will continue to expand the market of Anlotinib. In addition, the increase in indications will also increase sales. In the first half of 2021, Focavi’s fourth indication is in the state of approval in China. It is expected that with the approval of new indications in the future, the patient population of Anlotinib will expand, and sales value and sales volume will also increase to a certain extent.
- The impact of COVID-19 on China's Anlotinib market
- Sales value of China's Anlotinib 2016-2020
- Competitive landscape of China's Anlotinib market
- Prices of Anlotinib in China
- Prices of Anlotinib in China by regions and manufacturers
- Analysis of factors affecting the development of China's Anlotinib market
- Prospect of China's Anlotinib market from 2021 to 2025
1.1 Indications for Anlotinib
1.2 Development of Anlotinib in China
1.3 Governmental Approval of Anlotinib in China
1.4 The Impact of COVID-19 on Anlotinib sales in China
2 Sales of Anlotinib in China, 2018-2020
2.1 Sales Value of Anlotinib
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Anlotinib
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Anlotinib by Dosage Form in China, 2018-2020
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Anlotinib Manufacturers in China, 2018-2020
3.1 Analysis of Market Share of Major Anlotinib Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Jiangsu Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Fukewei (Jiangsu Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.’s Anlotinib) in China
4 Prices of Anlotinib for Different Manufacturers in China, 2020-2021
4.1 Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd. (Fukewei)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Anlotinib drug Market, 2021-2025
5.1 Influential Factors of Chinese Anlotinib Market Development
5.1.1 The Impact of COVID-19 on Chinese Anlotinib Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Anlotinib Capsules Registration in China
Chart Sales Value of Anlotinib Capsules over the World
Chart Sales Value of Anlotinib Capsules in China, 2018-2020
Chart Sales Value of Anlotinib Capsules in China by Region, 2018-2020
Chart Sales Volume of Anlotinib Capsules in China, 2018-2020
Chart Sales Volume of Anlotinib Capsules in China by Region, 2018-2020
Chart Market Share by Sales Value of Top Anlotinib Manufacturers in China, 2018-2020
Chart Sales Value and Volume of Fukewei in China, 2018-2020
Chart Referential Prices of Fukewei in China, 2020-2021
Chart Forecast on Sales Value of Anlotinib in China, 2021-2025
Chart Forecast on Sales Volume of Anlotinib in China, 2021-2025
- Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.